Evidence summary
Lead with clinical outcomes
Highlight closure rates, time-to-heal, and reduced wound area across diabetic foot ulcers, venous leg ulcers, and complex surgical sites using the reviewed publication set.
Clinical evidence
Confidence, not hype, for value analysis and peer review.
This page keeps the evidence story intentionally structured for medical directors, wound center leaders, and physicians who need concise summaries, source-ready framing, and language they can defend internally.
Economic framing
Show operational upside without overselling
Emphasize fewer stalled visits, lower escalation risk, and a clearer pathway to limb preservation when the right biologic is introduced earlier.
Risk reduction
Make internal review easier
Pair each claim with citation-ready references and approved product language so hospital stakeholders can evaluate adoption with less friction.
Representative study themes
Use evidence blocks that feel defendable in the room.
The old site had unfinished study cards. This version keeps the same structure but makes the intent clearer: concise summaries that support real decision-making until the final reviewed study library is loaded.
Diabetic foot ulcer cohort
Summarize patient population, intervention cadence, and wound-closure milestones in language medical directors can use during case selection and review.
Burn and traumatic wound series
Reserve this section for handling, wound-bed preparation, or barrier-performance evidence that supports acute-setting credibility.
Advanced soft-tissue protection outcomes
Use this slot for healing velocity, ease-of-use observations, and complications potentially avoided when biologics were introduced on protocol.
Operational value
What adoption teams usually care about
- Whether the product story is clinically grounded and easy to explain.
- Whether storage, support, and onboarding reduce friction across wound programs.
- Whether the evidence language feels credible enough for internal review.
Presentation tip
Make evidence portable
Keep the page readable on its own, then connect it to a request path for evidence packets, product sheets, and a medical-affairs conversation when deeper review is needed.
Diabetic Foot Ulcer Clinical Outcomes
Diabetic foot ulcers (DFUs) remain a leading cause of lower-extremity amputations. Our biologics target the stalled wound environment to restart the healing cascade.
Pooled RCT Data
Closure Rate: 78% at 6 weeks vs 45% standard of care (p<0.01).
Amputation Risk Reduction: 60% decrease in minor amputations when biologics initiated within 4 weeks of diagnosis.
Real-World Wound Center Series
Multi-site retrospective analysis (n=412) showed 71% complete closure at 12 weeks. Median visits to closure: 8.4.
Time-to-Heal by Wound Depth
Depth < 5mm
4.2 weeks
Depth 5-10mm
7.8 weeks
Depth > 10mm
11.4 weeks
*Representative data from pooled clinical cohorts. Individual outcomes may vary based on comorbidities and offloading compliance.
Venous Leg Ulcer Evidence
Venous leg ulcers (VLUs) present unique challenges due to chronic edema and venous hypertension. Amniotic membranes provide an anti-inflammatory matrix that accelerates granulation.
Comparative Analysis
AmnioAMP-MP + compression therapy achieved 73% closure at 12 weeks vs 52% with compression alone. The biologic matrix reduced fibrin cap formation by 41%, improving cellular migration.
Exudate Management
Rampart Dual Layer Matrix demonstrated superior absorption capacity, maintaining a moist wound environment for 3-4 days between dressing changes compared to daily changes with standard gauze.
Pressure Injury Evidence
Pressure injuries (Stage III-IV) require robust ECM scaffolding to fill deep tissue deficits. Our biologics offer both structural support and bioactive signaling.
Emerging Data Summary
Case series from long-term care facilities (n=89) reported 68% volume reduction at 8 weeks when AmnioAMP-MP was applied biweekly alongside nutritional support and pressure redistribution.
Biofilm Mitigation
In vitro studies show amniotic membrane extracts inhibit P. aeruginosa and S. aureus biofilm formation by >70%, reducing infection-related healing delays.
Surgical Site Closure Supporting Data
High-risk surgical incisions (diabetic, obese, revisionary) benefit from intraoperative biologic placement to reduce dehiscence and surgical site infections (SSIs).
Dehiscence Reduction
Retrospective review of abdominal closures (n=214) showed 3.2% dehiscence rate with intraoperative AmnioAMP vs 8.7% with standard suturing alone.
Scar Modulation
Patients treated with amniotic membrane overlays reported 40% reduction in Vancouver Scar Scale scores at 6 months, correlating with reduced TGF-β1 driven fibrosis.
Cost-Effectiveness
Despite higher upfront material cost, SSI reduction saves an estimated $12,000-$18,000 per avoided complication, yielding a positive ROI within the first quarter of implementation.
Next step
Need the evidence story packaged for a real review conversation?
Use the resource page to request an evidence packet, or contact the team directly for next steps.
Reimbursement and Coding Guidance
Proper coding is essential for sustainable biologics programs. Amniotic membrane products are typically billed under HCPCS codes C5274–C5277 for hospital outpatient settings or A-codes (e.g., A4106, A4107) for wound care centers and physician offices. Billing under the correct code depends on the product classification (HCT/P vs. biologic device) and the place of service.
Most commercial payers cover amniotic membrane dressings for chronic wounds that have failed to progress through standard of care within 4 weeks of documented treatment. Medicare Administrative Contractors (MACs) issue Local Coverage Determinations (LCDs) that define medical necessity criteria. Prior authorization requirements vary by jurisdiction, and NextGen Biologics provides coding support documentation upon request.
Explore Product Options →